Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Type:
Grant
Filed:
December 22, 2008
Date of Patent:
February 5, 2013
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
Type:
Grant
Filed:
January 19, 2011
Date of Patent:
January 29, 2013
Assignee:
Xencor, Inc.
Inventors:
Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Type:
Grant
Filed:
February 1, 2010
Date of Patent:
December 25, 2012
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Application
Filed:
August 24, 2012
Publication date:
December 20, 2012
Applicant:
XENCOR, INC.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Type:
Grant
Filed:
February 1, 2010
Date of Patent:
December 4, 2012
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Type:
Grant
Filed:
February 1, 2010
Date of Patent:
November 27, 2012
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present invention is directed to the creation of human equivalent CDRs and antibodies containing them by a method of producing an antibody which specifically binds to an antigen.
Type:
Grant
Filed:
April 20, 2009
Date of Patent:
November 20, 2012
Assignee:
Xencor, Inc.
Inventors:
Matthew J. Bernett, Gregory Moore, John R. Desjarlais
Abstract: The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.
Type:
Application
Filed:
December 23, 2011
Publication date:
October 11, 2012
Applicant:
Xencor, Inc.
Inventors:
Bassil I. Dahiyat, Gregory A. Lazar, Omid Vafa
Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Type:
Application
Filed:
January 9, 2012
Publication date:
September 13, 2012
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Rudolph Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
Type:
Application
Filed:
December 23, 2011
Publication date:
September 6, 2012
Applicant:
Xencor, Inc.
Inventors:
Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Application
Filed:
November 21, 2011
Publication date:
June 21, 2012
Applicant:
Xencor, Inc.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Application
Filed:
November 10, 2011
Publication date:
June 21, 2012
Applicant:
Xencor, Inc.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Application
Filed:
November 21, 2011
Publication date:
June 14, 2012
Applicant:
XENCOR, INC.
Inventors:
SEUNG YUP CHU, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR, GREGORY L. MOORE, IGOR VOSTIAR
Abstract: The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Grant
Filed:
May 5, 2005
Date of Patent:
May 29, 2012
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
Type:
Application
Filed:
December 15, 2011
Publication date:
April 12, 2012
Applicant:
XENCOR, INC.
Inventors:
AARON KEITH CHAMBERLAIN, BASSIL I. DAHIYAT, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR
Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Type:
Grant
Filed:
October 29, 2007
Date of Patent:
February 28, 2012
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
Type:
Application
Filed:
July 29, 2011
Publication date:
February 2, 2012
Applicant:
XENCOR, INC.
Inventors:
Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett
Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
Type:
Grant
Filed:
January 25, 2008
Date of Patent:
January 24, 2012
Assignee:
Xencor, Inc.
Inventors:
Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa